Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alkermes
Biotech
Alkermes impresses in full-throttle narcolepsy race with Takeda
The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect despite being administered less frequently.
Nick Paul Taylor
Jun 4, 2024 9:01am
Mural wants to paint new picture in IL-2 after Alkermes spinout
Nov 15, 2023 8:56am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
Alkermes shines light on early cancer, neuro assets
Mar 26, 2021 8:55am
Alkermes sees swift turnaround for rejected schizophrenia med
Dec 29, 2020 8:18am
FDA panel clashes over Alkermes' schizophrenia med's risks
Oct 9, 2020 7:00pm
